🎉 M&A multiples are live!
Check it out!

HK inno.N Valuation Multiples

Discover revenue and EBITDA valuation multiples for HK inno.N and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

HK inno.N Overview

About HK inno.N

HK Inno N Corp manufactures pharmaceutical products.


Founded

HQ

South Korea
Employees

n/a

Website

inno-n.com

Financials

LTM Revenue $631M

LTM EBITDA $91.3M

EV

$957M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

HK inno.N Financials

HK inno.N has a last 12-month revenue of $631M and a last 12-month EBITDA of $91.3M.

In the most recent fiscal year, HK inno.N achieved revenue of $611M and an EBITDA of $85.9M.

HK inno.N expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See HK inno.N valuation multiples based on analyst estimates

HK inno.N P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $565M $611M XXX XXX XXX
Gross Profit $238M $256M XXX XXX XXX
Gross Margin 42% 42% XXX XXX XXX
EBITDA $69.9M $85.9M XXX XXX XXX
EBITDA Margin 12% 14% XXX XXX XXX
Net Profit $26.0M $32.2M XXX XXX XXX
Net Margin 5% 5% XXX XXX XXX
Net Debt $233M $219M XXX XXX XXX

Financial data powered by Morningstar, Inc.

HK inno.N Stock Performance

As of April 15, 2025, HK inno.N's stock price is KRW 37000 (or $25).

HK inno.N has current market cap of KRW 1.05T (or $714M), and EV of KRW 1.40T (or $957M).

See HK inno.N trading valuation data

HK inno.N Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$957M $714M XXX XXX XXX XXX $1.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

HK inno.N Valuation Multiples

As of April 15, 2025, HK inno.N has market cap of $714M and EV of $957M.

HK inno.N's trades at 1.5x LTM EV/Revenue multiple, and 10.5x LTM EBITDA.

Analysts estimate HK inno.N's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for HK inno.N and 10K+ public comps

HK inno.N Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $957M XXX XXX XXX
EV/Revenue 1.6x XXX XXX XXX
EV/EBITDA 11.1x XXX XXX XXX
P/E 17.0x XXX XXX XXX
P/E/Growth 0.8x XXX XXX XXX
EV/FCF -70.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get HK inno.N Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

HK inno.N Valuation Multiples

HK inno.N's NTM/LTM revenue growth is 10%

HK inno.N's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, HK inno.N's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate HK inno.N's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for HK inno.N and other 10K+ public comps

HK inno.N Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 8% XXX XXX XXX XXX
EBITDA Margin 14% XXX XXX XXX XXX
EBITDA Growth 23% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 24% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 18% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 3% XXX XXX XXX XXX
Opex to Revenue 39% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

HK inno.N Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

HK inno.N M&A and Investment Activity

HK inno.N acquired  XXX companies to date.

Last acquisition by HK inno.N was  XXXXXXXX, XXXXX XXXXX XXXXXX . HK inno.N acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by HK inno.N

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About HK inno.N

Where is HK inno.N headquartered? HK inno.N is headquartered in South Korea.
Who is the CEO of HK inno.N? HK inno.N's CEO is Mr. Dal-Won Kwak.
Is HK inno.N publicy listed? Yes, HK inno.N is a public company listed on KRX.
What is the stock symbol of HK inno.N? HK inno.N trades under 195940 ticker.
When did HK inno.N go public? HK inno.N went public in 2021.
Who are competitors of HK inno.N? Similar companies to HK inno.N include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of HK inno.N? HK inno.N's current market cap is $714M
What is the current revenue of HK inno.N? HK inno.N's last 12-month revenue is $631M.
What is the current EBITDA of HK inno.N? HK inno.N's last 12-month EBITDA is $91.3M.
What is the current EV/Revenue multiple of HK inno.N? Current revenue multiple of HK inno.N is 1.5x.
What is the current EV/EBITDA multiple of HK inno.N? Current EBITDA multiple of HK inno.N is 10.5x.
What is the current revenue growth of HK inno.N? HK inno.N revenue growth between 2023 and 2024 was 8%.
Is HK inno.N profitable? Yes, HK inno.N is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.